EU says MS drug Gilenya needs heart monitoring
EU says MS drug Gilenya needs heart monitoring
The European Medicines Agency advised doctors to continuously monitor patients for six hours after giving them a first dose of Novartis AG's multiple sclerosis drug Gilenya, casting a shadow over the potential blockbuster product.
The move came as the organisation started a review into the safety of the medicine, following reports of heart problems in patients and the death of one person in the United States within 24 hours of starting treatment.
The Swiss drugmaker said last month it was investigating whether Gilenya, seen by analysts as a potential multibillion-dollar seller, caused the death of the 59-year-old U.S. patient....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... geid/1309/
MS-UK - http://www.ms-uk.org/
Re: EU says MS drug Gilenya needs heart monitoring
thanks for sharing
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1221 Views
-
Last post by frodo
-
- 1 Replies
- 1285 Views
-
Last post by NHE
-
- 0 Replies
- 1649 Views
-
Last post by NHE
-
- 0 Replies
- 2321 Views
-
Last post by DIM
-
- 0 Replies
- 654 Views
-
Last post by NHE
-
- 0 Replies
- 1723 Views
-
Last post by NHE
-
- 1 Replies
- 3352 Views
-
Last post by Tif
-
- 0 Replies
- 294 Views
-
Last post by DIM
-
- 2 Replies
- 1222 Views
-
Last post by DIM